Shionogi & Co. Ltd.’s share price plunged in morning trading in Tokyo on 23 June following a surprise decision the previous day from an advisory panel considering the emergency approval of its oral COVID-19 drug Xocova (ensitrelvir; S-217622).
Shionogi Hit By Surprise Japan Road Bump For Oral COVID Drug
After months of speculation and anticipation, Shionogi’s once-daily oral antiviral for the treatment of COVID-19 has stumbled after receiving an unexpected preliminary decision on its emergency approval from an advisory committee in Japan.
